A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network

Author:

Bernard Gordon R.,Harris Paul A.,Pulley Jill M.,Benjamin Daniel K.,Dean Jonathan Michael,Ford Daniel E.,Hanley Daniel F.,Selker Harry P.,Wilkins Consuelo H.

Abstract

Inefficiencies in the national clinical research infrastructure have been apparent for decades. The National Center for Advancing Translational Science—sponsored Clinical and Translational Science Award (CTSA) program is able to address such inefficiencies. The Trial Innovation Network (TIN) is a collaborative initiative with the CTSA program and other National Institutes of Health (NIH) Institutes and Centers that addresses critical roadblocks to accelerate the translation of novel interventions to clinical practice. The TIN’s mission is to execute high-quality trials in a quick, cost-efficient manner. The TIN awardees are composed of 3 Trial Innovation Centers, the Recruitment Innovation Center, and the individual CTSA institutions that have identified TIN Liaison units. The TIN has launched a national scale single (central) Institutional Review Board system, master contracting agreements, quality-by-design approaches, novel recruitment support methods, and applies evidence-based strategies to recruitment and patient engagement. The TIN has received 113 submissions from 39 different CTSA institutions and 8 non-CTSA Institutions, with projects associated with 12 different NIH Institutes and Centers across a wide range of clinical/disease areas. Already more than 150 unique health systems/organizations are involved as sites in TIN-related multisite studies. The TIN will begin to capture data and metrics that quantify increased efficiency and quality improvement during operations.

Publisher

Cambridge University Press (CUP)

Subject

General Medicine

Reference13 articles.

1. A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors

2. Peters S . Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published. Tufts Center for the Study of Drug Development News [Internet], 2016 [cited May 6, 2016]. (http://csdd.tufts.edu/news/complete_story/tufts_csdd_rd_cost_study_now_published)

3. Hess J . Clinical Trial Delays Cost Pharmaceutical Companies. Cutting Edge Information [Internet], 2005 [cited Jan 22, 2017]. (http://www.prnewswire.com/news-releases/clinical-trial-delays-cost-pharmaceutical-companies-55044607.html)

4. A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials

5. Why Most Published Research Findings Are False

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3